Exemestane Capsules

The growth of breast cancer cells can be dependent on the presence of estrogen. The estrogen (estrone and estradiol) in the circulation of postmenopausal women is mainly converted by aromatase in peripheral tissues from androgens (androstenedione and testosterone) in the adrenal glands and ovaries. Preventing estrogen production by inhibiting aromatase is an effective and selective treatment for postmenopausal hormone-dependent breast cancer. Exemestane is an irreversible steroid aromatase inactivator. It is structurally similar to the enzyme's natural substrate, androstenedione, and is a pseudo-substrate of aromatase. It can inactivate the enzyme by irreversibly binding to its active site (this effect is also called "self-destructive inhibition"), thereby significantly reducing the level of estrogen in the blood circulation of menopausal women, but has no effect on the biosynthesis of corticosteroids and aldosterone in the adrenal glands.

Exemestane

This product is a hard capsule, and the content is off-white powder.

It is indicated for postmenopausal patients with advanced breast cancer whose disease has progressed after treatment with tamoxifen.

Take one tablet (25 mg) orally once a day after meals. No dosage adjustment is required for patients with mild hepatic and renal impairment.

The main adverse reactions of this product are: nausea, dry mouth, constipation, diarrhea, dizziness, insomnia, rash, fatigue, fever, edema, pain, vomiting, abdominal pain, increased appetite, weight gain, etc. In addition, the literature also reports hypertension, depression, anxiety, dyspnea, and cough. Others include decreased lymphocyte counts and abnormal liver function indicators (such as alanine transferase, etc.). In clinical trials, only 3% of patients terminated treatment due to adverse reactions, mainly within the first 10 weeks of exemestane treatment: termination of treatment due to adverse reactions in the later period is uncommon (0.3%).

Patients who are allergic to this product or its excipients are contraindicated.

Precautions for children: Forbidden Precautions for pregnancy and lactation: Forbidden Precautions for the elderly: No special precautions

This product should not be used in combination with estrogen drugs to avoid antagonizing the pharmacodynamic effects of this product; Exemestane is mainly metabolized by cytochrome P-4503A4 (CYP3A4), but when used in combination with a strong CYP3A4 inhibitor (ketoconazole), the pharmacokinetics of this product did not change, so it seems that CYP isoenzyme inhibitors have no significant effect on the pharmacokinetics of this product. However, the possibility that known CYP3A4 inducers reduce the level of exemestane in plasma cannot be ruled out.

Keep sealed. The validity period is tentatively set at one and a half years.

25mg

18 months

Hangzhou Minsheng Pharmaceutical Co., Ltd.

• Founded in:

  1963-11-29

• Address:

  No. 36, Linping Avenue, Donghu Street, Linping District, Hangzhou City, Zhejiang Province

• Tax NO.:

  913301101430685558

• Registered Funds:

  88.97 million yuan

• Website:

  Log in to view

• Email:

  Log in to view